Wells Fargo Downgrades King Pharmaceuticals (KG) To Market Perform On Proposed Acquisition By PFE
Tweet Send to a Friend
Wells Fargo downgrades King Pharmaceuticals (NYSE: KG) from Outperform to Market Perform. Valuation range raised from $11-12 to $14-15.
Wells ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wells ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
